BACKGROUND:Antiretroviral therapy (ART)-mediated immune reconstitution fails to restore the capacity of the immune system to spontaneously control human immunodeficiency virus (HIV) replication. METHODS: A total of 23 HIV type 1 (HIV-1)-infected, virologically suppressed subjects receiving ART (CD4(+) T-cell count, >450 cells/μL) were randomly assigned to have 180 μg/week (for arm A) or 90 μg/week (for arm B) of pegylated (Peg) interferon alfa-2a added to their current ART regimen. After 5 weeks, ART was interrupted, and Peg-interferon alfa-2a was continued for up to 12 weeks (the primary end point), with an option to continue to 24 weeks. End points included virologic failure (viral load, ≥ 400 copies/mL) and adverse events. Residual viral load and HIV-1 DNA integration were also assessed. RESULTS: At week 12 of Peg-interferon alfa-2a monotherapy, viral suppression was observed in 9 of 20 subjects (45%), a significantly greater proportion than expected (arm A, P = .0088; arm B, P = .0010; combined arms, P < .0001). Over 24 weeks, both arms had lower proportions of subjects who had viral load, compared with the proportion of subjects in a historical control group (arm A, P = .0046; arm B, P = .0011). Subjects who had a sustained viral load of <400 copies/mL had decreased levels of integrated HIV DNA (P = .0313) but increased residual viral loads (P = .0078), compared with subjects who experienced end-point failure. CONCLUSIONS:Peg-interferon alfa-2aimmunotherapy resulted in control of HIV replication and decreased HIV-1 integration, supporting a role for immunomediated approaches in HIV suppression and/or eradication. CLINICAL TRIALS REGISTRATION: NCT00594880.
RCT Entities:
BACKGROUND: Antiretroviral therapy (ART)-mediated immune reconstitution fails to restore the capacity of the immune system to spontaneously control human immunodeficiency virus (HIV) replication. METHODS: A total of 23 HIV type 1 (HIV-1)-infected, virologically suppressed subjects receiving ART (CD4(+) T-cell count, >450 cells/μL) were randomly assigned to have 180 μg/week (for arm A) or 90 μg/week (for arm B) of pegylated (Peg) interferon alfa-2a added to their current ART regimen. After 5 weeks, ART was interrupted, and Peg-interferon alfa-2a was continued for up to 12 weeks (the primary end point), with an option to continue to 24 weeks. End points included virologic failure (viral load, ≥ 400 copies/mL) and adverse events. Residual viral load and HIV-1 DNA integration were also assessed. RESULTS: At week 12 of Peg-interferon alfa-2a monotherapy, viral suppression was observed in 9 of 20 subjects (45%), a significantly greater proportion than expected (arm A, P = .0088; arm B, P = .0010; combined arms, P < .0001). Over 24 weeks, both arms had lower proportions of subjects who had viral load, compared with the proportion of subjects in a historical control group (arm A, P = .0046; arm B, P = .0011). Subjects who had a sustained viral load of <400 copies/mL had decreased levels of integrated HIV DNA (P = .0313) but increased residual viral loads (P = .0078), compared with subjects who experienced end-point failure. CONCLUSIONS: Peg-interferon alfa-2a immunotherapy resulted in control of HIV replication and decreased HIV-1 integration, supporting a role for immunomediated approaches in HIV suppression and/or eradication. CLINICAL TRIALS REGISTRATION: NCT00594880.
Authors: Hiroyu Hatano; Eric L Delwart; Philip J Norris; Tzong-Hae Lee; Torsten B Neilands; Colleen F Kelley; Peter W Hunt; Rebecca Hoh; Jeffrey M Linnen; Jeffrey N Martin; Michael P Busch; Steven G Deeks Journal: AIDS Date: 2010-10-23 Impact factor: 4.177
Authors: Alasdair Leslie; Philippa C Matthews; Jennifer Listgarten; Jonathan M Carlson; Carl Kadie; Thumbi Ndung'u; Christian Brander; Hoosen Coovadia; Bruce D Walker; David Heckerman; Philip J R Goulder Journal: J Virol Date: 2010-07-21 Impact factor: 5.103
Authors: Margalida Rotger; Kristen K Dang; Jacques Fellay; Erin L Heinzen; Sheng Feng; Patrick Descombes; Kevin V Shianna; Dongliang Ge; Huldrych F Günthard; David B Goldstein; Amalio Telenti Journal: PLoS Pathog Date: 2010-02-26 Impact factor: 6.823
Authors: David Palesch; Steven E Bosinger; Maud Mavigner; James M Billingsley; Cameron Mattingly; Diane G Carnathan; Mirko Paiardini; Ann Chahroudi; Thomas H Vanderford; Guido Silvestri Journal: J Virol Date: 2018-06-29 Impact factor: 5.103
Authors: M Christian Tjiam; James P A Taylor; Mazmah A Morshidi; Lucy Sariputra; Sally Burrows; Jeffrey N Martin; Steven G Deeks; Dino B A Tan; Silvia Lee; Sonia Fernandez; Martyn A French Journal: J Immunol Date: 2015-04-24 Impact factor: 5.422
Authors: Anjie Zhen; Valerie Rezek; Cindy Youn; Brianna Lam; Nelson Chang; Jonathan Rick; Mayra Carrillo; Heather Martin; Saro Kasparian; Philip Syed; Nicholas Rice; David G Brooks; Scott G Kitchen Journal: J Clin Invest Date: 2016-12-12 Impact factor: 14.808